Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients

Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients

2024.01.18
Fudan University Shanghai Cancer Center Are there differences in long-term prognosis between Asian and Caucasian patients with new metastatic prostate cancer (mPC)? A study presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) by Dr. Zhu Yao's team suggests that among patients receiving different treatment regimens, Asian males have superior overall survival (OS) and cancer-specific survival (CSS) compared to white males in this category. This research highlights the importance of considering Asians as an independent prognostic factor when evaluating individual patient outcomes and the need to include an adequate representation of Asian patients in the design of global multicenter clinical trials.
Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients, International Clinical Trial Designs Should Consider This Factor

Dr Zhu Yao’s Team: Significant Survival Differences in Newly Diagnosed mPC Patients between Asian and Caucasian patients, International Clinical Trial Designs Should Consider This Factor

2023.10.13
Are there differences in long-term prognosis between Asian and Caucasian patients with new metastatic prostate cancer (mPC)? A study presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) by Dr. Zhu Yao's team suggests that among patients receiving different treatment regimens, Asian males have superior overall survival (OS) and cancer-specific survival (CSS) compared to white males in this category. This research highlights the importance of considering Asians as an independent prognostic factor when evaluating individual patient outcomes and the need to include an adequate representation of Asian patients in the design of global multicenter clinical trials.